OTC Deficiency clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for

  • DTX301 AAV- Mediated Gene Transfer for Ornithine Transcarbamylase(OTC) Deficiency

    Sorry, in progress, not accepting new patients

    The primary objective is to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels with removal of dietary protein restriction and alternative pathway medication.

    Los Angeles, California and other locations

Our lead scientists for OTC Deficiency research studies include .

Last updated: